Tianshu Liu

3 ta ish

Fudan University

1. Claudin-18 isoform 2-specific CAR T-cell therapy (satri-cel) versus treatment of physician's choice for previously treated advanced gastric or gastro-oesophageal junction cancer (CT041-ST-01): a randomised, open-label, phase 2 trial

   Changsong Qi, Chang Liu, Zhi Peng +31

   MaqolaOAOchiq kirish20252 iqtibos

   ABIABI:AkademIndex/2026.other.103004

2. Epigenetic regulation of cancer progression by EZH2: from biological insights to therapeutic potential

   Lu Gan, Yanan Yang, Qian Li +3

   Sharh maqola20182 iqtibos

   ABIABI:AkademIndex/2026.other.431280

3. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial

   Yelena Y. Janjigian, Kohei Shitara, Markus Moehler +26

   Maqola20212 iqtibos

   ABIABI:AkademIndex/2026.other.596966